Sometimes there is a temptation to use a treatment protocol, which has shown to be successful for one type of cancer more widely. An example of this is the application of Neoadjuvant chemo (Neo) prior to surgery for rarer types of ovarian cancer. Although Neo is beneficial for High Grade Serous Ovarian Cancer, it seems to be ineffective for other types.
This retrospective review looked at about 1000 cases of Low Grade Serous Ovarian Cancer in women who presented with advanced disease (stage III-IV), during the period 2006-2019. There was a gradual increase in the number receiving Neo, with 15% having delayed surgery with Neo beforehand.
When the data was reviewed in 2022, no benefit was shown with survival worse for those who had Neo, and larger residual volumes after initial surgery. Similar failed Neo, with worse outcomes, were seen for women with Clear Cell Ovarian Cancer and Mucinous Ovarian cancer.
No comments:
Post a Comment